54 related articles for article (PubMed ID: 27080437)
1. Risk of systemic lymphoma in patients with cutaneous CD30+ lymphoproliferative disorders: A single center retrospective cohort analysis.
Chen J; Martinez A; Shinohara MM
J Am Acad Dermatol; 2024 Mar; ():. PubMed ID: 38490370
[No Abstract] [Full Text] [Related]
2. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
3. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma.
Castaneda CA; Castillo M; Torres-Cabala C; Bernabe LA; Casavilca S; Villegas V; Sanchez J; de la Cruz M; Dunstan J; Cotrina JM; Gomez HL; Chavez C; Landa-Baella MP; Tello K; Felix BF; Abugattas J
Clin Transl Oncol; 2019 Sep; 21(9):1127-1134. PubMed ID: 30778854
[TBL] [Abstract][Full Text] [Related]
4. Prurigo Nodularis in a Patient with Anaplastic Large Cell Lymphoma: A Potential Role for M2-Macrophages in Its Pathogenesis.
Hashimoto T; Namiki T; Iikawa M; Ugajin T; Miura K; Yokozeki H
Ann Dermatol; 2022 Apr; 34(2):149-151. PubMed ID: 35450319
[No Abstract] [Full Text] [Related]
5. Diagnostic utility of plasmacytoid dendritic cells in dermatopathology.
Bardawil T; Khalil S; Kurban M; Abbas O
Indian J Dermatol Venereol Leprol; 2021; 87(1):3-13. PubMed ID: 33580939
[TBL] [Abstract][Full Text] [Related]
6. [Primary cutaneous CD30+ lymphoproliferative disorders].
Calzado-Villarreal L; Polo-Rodríguez I; Ortiz-Romero PL
Actas Dermosifiliogr; 2010 Mar; 101(2):119-28. PubMed ID: 20223154
[TBL] [Abstract][Full Text] [Related]
7. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
Kempf W
J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
9. Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
Martires KJ; Ra S; Abdulla F; Cassarino DS
Am J Dermatopathol; 2015 Nov; 37(11):822-33. PubMed ID: 26485239
[TBL] [Abstract][Full Text] [Related]
10. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the tumor microenvironment in primary cutaneous CD30-positive lymphoproliferative disorders: a predominance of CD163-positive M2 macrophages.
De Souza A; Tinguely M; Burghart DR; Berisha A; Mertz KD; Kempf W
J Cutan Pathol; 2016 Jul; 43(7):579-88. PubMed ID: 27080437
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
